Intrasense DUOnco Pancreas wins Japan regulatory approval

• Intrasense’s DUOnco Pancreas won regulatory clearance in Japan, opening the market for commercialization of the Guerbet-partnered oncology AI product.
• DUOnco Unity is nearing completion, with CE marking expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intrasense SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.